Moreover, a triple monoclonal therapy regimen (trastuzumab, pertuzumab, and docetaxel) was investigated in pre-treated HER2-mutant NSCLC, showing a better response duration compared with T-DXd [42]. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.